Skip to content

Anika Therapeutics ANIK Q1 2024 Annual earnings

Reported May 8, 2024 · After market close

Revenue$40.5MBeat by $1.3M
EPS-$0.31Miss by $0.12
Revenue estimate$39.2M
EPS estimate-$0.19

Next report

Date not yet announced

Financials

Q1 2024

Income statement

See full
Revenue$40.5M+6.9%
Net income-$4.5M+56.4%

Balance sheet

See full
Cash & equivalents$68.6M-13.9%
Total debt$28.5M+0.7%
Total equity$208.5M-24.9%
Total assets$263.7M-22.2%

Cash flow

See full
Operating cash flow-$126.0K+96.5%
CapEx$1.8M+30.2%
Free cash flow-$1.9M+61.4%

Valuation & ratios

Valuation

as of 03/31/24
See full
Market cap$377.19M-10.2%
Enterprise value$337.03M-8.6%
P/S2.2×-0.4×

Profitability

See full
Net margin-45.4%-82.9pp

Returns & leverage

See full
Return on equity-31.6%-47.4pp
Debt / equity0.1×0.0×
Current ratio5.6×0.0×

Segments

By geography

See full
Europe$6.0M+5.4%
Other Location$5.3M+6.9%

By product

See full
OEM Channel$19.5M-8.1%
Commercial Channel$9.6M+5.9%

Versus estimates

Ask the moment Anika Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Anika Therapeutics report Q1 2024 earnings?
Anika Therapeutics (ANIK) reported Q1 2024 earnings on May 8, 2024 after market close.
What were Anika Therapeutics's Q1 2024 revenue and EPS?
Anika Therapeutics reported revenue of $40.5M and eps of $-0.31 for Q1 2024.
Did Anika Therapeutics beat estimates in Q1 2024?
Revenue beat the consensus estimate of $39.2M by $1.3M. EPS missed the consensus estimate of $-0.19 by $0.12.
Where can I find Anika Therapeutics's Q1 2024 SEC filings?
You can read the 10-K/A periodic report (0001171843-24-002274) directly on SEC EDGAR. The filing index links above go to sec.gov.